Zealand Pharma AS (STU:22Z) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:22Z Zealand Pharma AS STU:22Z
42 GF Score
Price €42.52
GF Value €1,546.27
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Zealand Pharma AS Defensive Interval Ratio?

STU:22Z
42GF Score
Zealand Pharma AS STU:22Z
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zealand Pharma AS (STU:22Z) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of €42.52 is trading 97.3% below its estimated GF Value™ of €1,546.27. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for STU:22Z:

  • Defensive Interval Ratio:
  • GF Value™: €1,546.27 vs. price of €42.52 (97.3% below fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the STU:22Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
42GF Score

Get the complete analysis for STU:22Z

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.52
Price
€1,546.27
GF Value